HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

摘要

Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.

主权项

1. A composition comprising at least two HLA-binding peptides, wherein:
(a) at least one of said at least two HLA-binding peptides is a peptide consisting of an epitope according to SEQ ID NO: 23 or a fusion protein of SEQ ID NO: 23 and the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain, and (b) at least one of said at least two peptides is a peptide consisting of an epitope selected from the group consisting of: SEQ ID NO:1 to SEQ ID NO: 11, SEQ ID NO: 13 to SEQ ID NO: 22, and SEQ ID NO: 24 to SEQ ID NO: 42.